Life Sciences

  • October 27, 2025

    Covington Helps Novartis Buy Avidity Biosciences For $12B

    Swiss pharmaceutical giant Novartis AG has said it will buy Avidity Biosciences, a U.S. developer of therapeutics for muscle diseases, for approximately $12 billion in a move to boost its neuroscience portfolio.

  • October 24, 2025

    Pfizer Hit With More Suits Over Depo-Provera

    Three women sued Pfizer this week in Florida federal court, alleging its hormonal contraceptive birth control shot Depo-Provera caused their brain tumors in the latest claims that the major drugmaker failed to warn of the link.

  • October 24, 2025

    Ohio, Ky. Reps Again Pursue Bill To Make PTAB Optional

    A bipartisan pair of legislators in the U.S. House of Representatives are floating a bill that would give patent owners the ability to extinguish challenges to their intellectual property at the Patent Trial and Appeal Board before they start.

  • October 24, 2025

    GNC Franchisee Cos. Largely Lose Bid To Toss Award Order

    An international court judge has largely denied efforts by GNC franchisee businesses in Singapore and the Philippines to set aside an order enforcing arbitral awards totaling about $45 million that also enforced a contractual obligation to assign their 54 stores in Singapore to the health and wellness company.

  • October 24, 2025

    USPTO Chief To Review PTAB Ruling On Tire Sensor Patent

    U.S. Patent and Trademark Office Director John Squires has decided to step in and examine a Patent Trial and Appeal Board decision from September to consider a challenge to a Cerebrum Sensor Technologies Inc. tire sensor patent.

  • October 24, 2025

    Tricida Investors Win OK Of $14.2M Deal Over Kidney Drug

    A California federal judge on Thursday granted final approval to a $14.2 million settlement that ends a class action against Tricida Inc. founder Gerrit Klaerner claiming he and the company misled investors on the approval chances for their new kidney disease drug, including nearly $4 million for plaintiffs' counsel.

  • October 24, 2025

    Generic-Drug Makers Want Conn. Price Cap Blocked During Suit

    A trade group for generic and biosimilar drugmakers is asking a Connecticut federal judge to block the state's new drug price cap during the pendency of its challenge, saying it illegally controls prices on sales made outside the state.

  • October 24, 2025

    Eli Lilly Buying Eye Disease Biotech For Up To $262M

    Ropes & Gray LLP-advised Eli Lilly said Friday it has agreed to acquire Cooley LLP-guided Adverum Biotechnologies, a clinical-stage company developing gene therapies for eye diseases, for up to roughly $262 million. 

  • October 24, 2025

    Abbott Wins Third Bellwether In Cow Milk Baby Formula MDL

    An Illinois federal judge has given Abbott Laboratories Inc. its third bellwether win in multidistrict litigation alleging that its cow-milk-based baby formula gives infants necrotizing enterocolitis, saying the company successfully demonstrated that the plaintiff's proffered human-milk-based alternative would not be feasible.

  • October 24, 2025

    Taxation With Representation: Latham, Wachtell, Gibson Dunn

    In this week's Taxation With Representation, Meta announces a joint venture with Blue Owl Capital to fund the development of a data center campus in Louisiana, private equity giants acquire medical technology company Hologic Inc., and National Fuel Gas Co. buys CenterPoint Energy Inc.'s Ohio natural gas utility business.

  • October 23, 2025

    NY AG Sues Vape Shop Owners For Selling To Kids

    New York's attorney general is looking to permanently shut down two smoke shops and ban their owners from ever working in the vape industry again, claiming they flagrantly sold illegal flavored vapes to customers including children, according to a petition filed Oct. 23.

  • October 23, 2025

    Ky. Rep. Revives Attempt To Abolish PTAB, Expand Eligibility

    U.S. Rep. Thomas Massie, R-Ky., said Thursday he's again attempting to overhaul the patent system, including abolishing the Patent Trial and Appeal Board, normalizing injunctions and broadening what can be patented.

  • October 23, 2025

    Chancery Maps Out Math For Hefty Drug Co. Breach Interest

    A Delaware vice chancellor late Thursday issued a road map for calculating tens of millions of dollars in interest due after a ruling in June that Alexion Pharmaceuticals failed a "best efforts" duty to fulfill an autoimmune drug candidate deal with Syntimmune Inc.

  • October 23, 2025

    Investor Says Biotech Co. Rigged Votes To Expand Share Pool

    A stockholder of Pennsylvania-based Ocugen Inc. sued the biotech company Thursday in Delaware Chancery Court, alleging that the company's board contrived a "clever" but unlawful scheme to push through a 2024 charter amendment that expanded its authorized share count without the required majority approval.

  • October 23, 2025

    RingConn Settles With Oura After ITC Import Ban

    Ouraring Inc. has inked a deal allowing RingConn to keep its smart rings on the U.S. market following the U.S. International Trade Commission's decision to block Ultrahuman and RingConn from importing products it held infringed a wearable computing device patent.

  • October 23, 2025

    Freshly Launched Legal Org. Plans To Protect Abortion Docs

    A new legal group launched this week aims to support telehealth doctors providing abortion pills and reproductive care, and to further strengthen shield laws protecting those providers from out-of-state prosecutions. 

  • October 23, 2025

    Bayer Wants Full Fed. Circ. Scrutiny Of Axed Xarelto Claims

    Bayer Pharma Aktiengesellschaft is urging the full Federal Circuit to scrutinize a decision that declined to revive claims in a patent covering its blockbuster blood thinner, saying Wednesday that a panel wrongly concluded the term "clinically proven effective" couldn't count toward the claims' patentability.

  • October 23, 2025

    SEC Being Misled In CBD Fraud Fight, CEO Claims

    The U.S. Securities and Exchange Commission has "unwittingly" taken the side of a former partner with a terminated licensing agreement, a pharmaceutical CEO told a California federal court this week, asking for summary judgment on the SEC's core claims that he defrauded investors.

  • October 23, 2025

    Ex-Exec Accused Of Stealing IVF Co.'s Trade Secrets

    The co-founder of a Garden State genetic testing company abruptly quit, deleted all the data on his company laptop — including the only copy of some materials — then took the trade secrets to help a competitor, according to a lawsuit filed in New Jersey federal court.

  • October 23, 2025

    Eli Lilly Says Pharmacy Mass-Producing Weight Loss Drug

    Drugmaker Eli Lilly is suing a compounding pharmacy in Texas federal court, alleging the pharmacy ripped off its lucrative weight loss drug, began mass-producing it, and made as much as $2 million per month last year from its misdeeds.

  • October 23, 2025

    Avadel, Jazz Settle Sleep Disorder Drug Claims

    Avadel Pharmaceuticals has announced it reached a global settlement with Irish rival Jazz Pharmaceuticals to dismiss their lawsuits against each other that alleged patent and antitrust violations related to sleep disorder drug Lumryz.

  • October 23, 2025

    Del. Startup Accuses Ex-CEO In Chancery Of Stock Scheme

    A Delaware pharmaceutical startup has sued its former CEO in the Delaware Chancery Court, accusing him of secretly enriching himself through unauthorized stock issuances and deceptive loans.

  • October 23, 2025

    Feds, Ex-Magellan CEO Still Split Over Sentencing Factors

    Lawyers for a former Magellan Diagnostics CEO and the government are still at odds over whether a judge should consider the product mislabeling charge she pled guilty to in March to be tantamount to fraud — an assertion the defense says is an attempt by prosecutors to "shoehorn" in allegations never put to proof.

  • October 23, 2025

    Buyers Sue Colgate Over Lead Found In Kids' Toothpaste

    A proposed class of buyers is suing Colgate-Palmolive Co. in California federal court, alleging that it sold children's toothpaste that contains substantial amounts of lead without warning consumers.

  • October 23, 2025

    5th Circ. Revives Religious Bias Suit Over DOD Vaccine Policy

    The Fifth Circuit breathed new life into a proposed class action claiming the U.S. Department of Defense unlawfully slow-walked civilian employees' requests for religious exemptions from its COVID-19 vaccination directive, saying the mandate getting rescinded didn't nullify the lawsuit.

Expert Analysis

  • What 2 Profs Noticed As Transactional Law Students Used AI

    Author Photo

    After a semester using generative artificial intelligence tools with students in an entrepreneurship law clinic, we came away with numerous observations about the opportunities and challenges such tools present to new transactional lawyers, say professors at Cornell Law School.

  • What Patent Claim 'Invalidity' Means In Different Forums

    Author Photo

    A recent Federal Circuit order allowing a patent suit to proceed despite similar claims being invalidated in an inter partes review underscores how fractured the patent litigation landscape has become, leading to critical nuances in how district courts, the U.S. International Trade Commission and Patent Trial and Appeal Board treat invalidity, says Jason Hoffman at BakerHostetler.

  • Rebuttal

    BigLaw Settlements Should Not Spur Ethics Deregulation

    Author Photo

    A recent Law360 op-ed argued that loosening law firm funding restrictions would make BigLaw firms less inclined to settle with the Trump administration, but deregulating legal financing ethics may well prove to be not merely ineffective, but counterproductive, says Laurel Kilgour at the American Economic Liberties Project.

  • How Big Pharma Has Responded To FTC Delisting Demands

    Author Photo

    Looking at some statistics concerning how pharmaceutical companies have responded to the Federal Trade Commission's recent challenges to Orange Book listings raises several possible hypotheses about the FTC's strategy and effectiveness, say Ratib Ali and Celia Lu at Competition Dynamics.

  • 5 Ways Lawyers Can Earn Back The Public's Trust

    Author Photo

    Amid salacious headlines about lawyers behaving badly and recent polls showing the public’s increasingly unfavorable view of attorneys, we must make meaningful changes to our culture to rebuild trust in the legal system, says Carl Taylor at Carl Taylor Law.

  • USPTO's AI Tool Redefines Design Patent Landscape

    Author Photo

    The U.S. Patent and Trademark Office's newly introduced DesignVision tool for artificial intelligence-powered image searching represents a dramatic shift in how design patent applications are examined, necessitating new strategies for patent practitioners, says Matthew Epstein at Dinsmore.

  • Class Actions At The Circuit Courts: August Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses key takeaways from federal appellate decisions involving topics including antitrust, immigration, consumer fraud, birthright citizenship under the Fourteenth Amendment, and product defects.

  • Series

    Hiking Makes Me A Better Lawyer

    Author Photo

    On the trail, I have thought often about the parallels between hiking and high-stakes patent litigation, and why strategizing, preparation, perseverance and joy are important skills for success in both endeavors, says Barbara Fiacco at Foley Hoag.

  • What US-India Trade Deal Will Mean For Indian Pharma

    Author Photo

    Complicated by newly imposed tariffs from the U.S., the outcome of the U.S.-India trade talks is poised to reshape not just trade policy, but also the strategic alignment of the two countries' pharmaceutical ecosystems, says Jashaswi Ghosh at Holon Law Partners.

  • Opinion

    Time For Full Disclosure Of Third-Party Funding In MDLs

    Author Photo

    It is appropriate that the Federal Advisory Committee on Civil Rules is considering a rule to require disclosure of third-party litigation funding in civil litigation — something that is particularly needed in multidistrict litigation, which now comprises more than half of all civil cases in the federal courts, says Eric Hudson at Butler Snow.

  • Series

    Law School's Missed Lessons: Negotiation Skills

    Author Photo

    I took one negotiation course in law school, but most of the techniques I rely on today I learned in practice, where I've discovered that the process is less about tricks or tactics, and more about clarity, preparation and communication, says Grant Schrantz at Haug Barron.

  • Conflicting Developments In Homelessness Legal Landscape

    Author Photo

    Looking at an executive order and Third Circuit opinion from last month highlights the ongoing tension in homelessness-related legal issues facing state and local governments, property owners, and individuals experiencing homelessness, says Josh Collins, an attorney for the City of South Salt Lake.

  • AG Watch: Texas Embraces The MAHA Movement

    Author Photo

    Attorneys at Kelley Drye examine Texas Attorney General Ken Paxton's actions related to the federal Make America Healthy Again movement, and how these actions hinge on representations or omissions by the target companies as opposed to specific analyses of the potential health risks.

  • Opinion

    Bar Exam Reform Must Expand Beyond A Single Updated Test

    Author Photo

    Recently released information about the National Conference of Bar Examiners’ new NextGen Uniform Bar Exam highlights why a single test is not ideal for measuring newly licensed lawyers’ competency, demonstrating the need for collaborative development, implementation and reform processes, says Gregory Bordelon at Suffolk University.

  • The Patent Eligibility Eras Tour: 11 Years Of Post-Alice Tumult

    Author Photo

    A survey of recent twists and turns in patent eligibility law highlights the confusion created by the U.S. Supreme Court's 2014 Alice decision and reveals that the continually shifting standards have begun to diverge in fundamental ways between the Federal Circuit and the U.S. Patent and Trademark Office, says Michael Shepherd at Fish & Richardson.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.